Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

78.11 +7.83 (+11.13%)
Streaming Delayed Price Updated: 11:46 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 555,304
Open 71.06
Bid (Size) 78.00 (400)
Ask (Size) 78.21 (300)
Prev. Close 70.28
Today's Range 70.76 - 78.36
52wk Range 36.88 - 78.54
Shares Outstanding 38,297,975
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire

Performance

YTD
+85.8%
+85.8%
1 Month
+8.2%
+8.2%
3 Month
+3.7%
+3.7%
6 Month
+55.2%
+55.2%
1 Year
+92.4%
+92.4%

More News

Read More
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' ↗
Via Stocktwits
News headline image
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 ↗
Via The Motley Fool
Topics Earnings
News headline image
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
Via The Motley Fool
News headline image
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗
Via Chartmill
News headline image
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock ↗
Via The Motley Fool
News headline image
Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge ↗
Via The Motley Fool
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
What Analysts Are Saying About Mirum Pharmaceuticals Stock ↗
Via Benzinga
News headline image
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Presents a Compelling Growth Momentum and Technical Setup ↗
Via Chartmill
News headline image
8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know ↗
Via Benzinga
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup ↗
Via Chartmill
News headline image
This Riot Platforms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
Via Benzinga
News headline image
Demystifying Mirum Pharmaceuticals: Insights From 6 Analyst Reviews ↗
Via Benzinga

Frequently Asked Questions

Is Mirum Pharmaceuticals, Inc. - common stock publicly traded?
Yes, Mirum Pharmaceuticals, Inc. - common stock is publicly traded.
What exchange does Mirum Pharmaceuticals, Inc. - common stock trade on?
Mirum Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Mirum Pharmaceuticals, Inc. - common stock?
The ticker symbol for Mirum Pharmaceuticals, Inc. - common stock is MIRM on the Nasdaq Stock Market
What is the current price of Mirum Pharmaceuticals, Inc. - common stock?
The current price of Mirum Pharmaceuticals, Inc. - common stock is 78.11
When was Mirum Pharmaceuticals, Inc. - common stock last traded?
The last trade of Mirum Pharmaceuticals, Inc. - common stock was at 12/19/25 11:46 AM ET
What is the market capitalization of Mirum Pharmaceuticals, Inc. - common stock?
The market capitalization of Mirum Pharmaceuticals, Inc. - common stock is 2.99B
How many shares of Mirum Pharmaceuticals, Inc. - common stock are outstanding?
Mirum Pharmaceuticals, Inc. - common stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.